Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/INmune Bio Inc./ 3

Initial Beneficial Ownership · 3

INmune Bio Inc.

INMBNASDAQEQUITYCurrent

Initial Beneficial Ownership

Filed Sep 16, 2026Accepted Sep 16, 2026, 8:05 PM EDTFiling CIK 1711754Accession 0001213900-26-100650
View company →Permanent SEC source ↗
Share

Structured filing — 3

ownership.xml

Open full document ↗

Filing details

Report period
2026-09-08
Issuer
Inmune Bio, Inc.
Issuer CIK
0001711754
Trading symbol
INMB
No securities owned
Checked

Reporting owner 1

Name
SAPIRSTEIN JAMES
Reporting owner CIK
0001559509
Relationship
Director
Address
C/O INMUNE BIO INC., 225 NE MIZNER BLVD., SUITE 640, BOCA RATON, FL, 33432

Signature 1

Signed
/s/ James Sapirsten
Date
2026-09-16

Company context

Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments for inflammation and immunology. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes. INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

Current securities

INMBNASDAQ · EQUITY · Current

Recent company filings

  1. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureOct 29, 2026
  2. 424B5 filingOct 29, 2026
  3. Regulation FD Disclosure · Other EventsOct 21, 2026
  4. 4 filingSep 17, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsSep 14, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.